Cutaneous adverse reactions to lenalidomide

• Autores: S. Imbesi, Alessandro Allegra, G. Calapai, Caterina Musolino, Sebastiano Gangemi
• Localización: Allergologia et immunopathologia: International journal for clinical and investigate allergology and clinical immunology, ISSN-e 1578-1267, ISSN 0301-0546, Vol. 43, Nº. 1, 2015, págs. 88-91
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Lenalidomide is an immunomodulatory drug (IMiD) used principally in the treatment of multiple myeloma (MM), myelodysplastic syndromes (MS) and amyloidosis.

    Adverse reactions related to lenalidomide include myelosuppression (mainly neutropenia but also thrombocytopenia), gastrointestinal problems, skin eruption, atrial fibrillation and asthenia, decreased peripheral blood stem cell yield during stem cell collection, venous thromboembolism, and secondary malignances. In this review we focused our attention on the cutaneous adverse reactions to lenalidomide.